Released Feb 28, 2019, after the close
10-K filed Mar 18, 2019, 77 days after period end · 0001171843-19-001793
Q4 2018 · 10-K
Revenue$33.86M$33.86M +56.4% vs Q4 2017+18.2% vs Q3 2018
Net Income$2.86M$2.86M +186.5% vs Q4 2017N/M vs Q3 2018
EPS Diluted$0.08$0.08 +166.7% vs Q4 2017N/M vs Q3 2018
Gross Profit$18,740,000+70.1%
Operating Income$1,742,000+365.8%
Operating Cash Flowderived$2,593,000N/M
Free Cash Flowderived$2,498,000N/M
Margins · derived
Gross margin55.3%+4.4 pt vs Q4 2017
Operating margin5.1%+3.4 pt vs Q4 2017
Net margin8.5%+3.8 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $33.86M | $21.65M | $26.42M | $28.37M |
| Net Income | $2.86M | $999.00K | -$1.32M | -$17.14M |
| EPS Diluted | $0.08 | $0.03 | -$0.04 | -$0.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR